Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales With SAFC(R)
August 03 2011 - 4:05PM
Marketwired
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS:
SBOTF) is pleased to announce they have entered into an agreement
for marketing and sales with SAFC®, a business unit of
Sigma-Aldrich (NASDAQ: SIAL) a global leader in biopharmaceutical
contract manufacturing. Under the agreement, Stellar will produce
KLH commercial intermediate and SAFC will sell, distribute and
market cGMP-grade HMW KLH (high molecular weight keyhole limpet
hemocyanin) that uses only Stellar aquaculture-derived KLH for
applications in therapeutic vaccines.
This collaboration is expected to increase access to a scalable
source for KLH, a critical immunostimulatory vaccine carrier
protein that will enable the transition from clinical research to
commercialization of conjugate vaccine platforms, while managing
costs and the risk of supply constraints faced by suppliers that
rely on the exploitation of the critically limited natural
resource.
Stellar will supply all aquaculture-derived KLH intermediate
required for production of SAFC cGMP KLH formulations. SAFC will
manufacture HMW KLH under cGMP conditions and provide cGMP clinical
and commercial manufacturing of bioconjugation services to support
the development and manufacture of conjugate vaccines.
SAFC Director of Business Development Tom Gelineau said, "Our
agreement with Stellar Biotechnologies reinforces SAFC's commitment
to providing high quality products and specialized contract
manufacturing resources to global biopharmaceutical customers --
from research through commercialization."
Stellar CEO Frank Oakes commented, "The agreement solidifies our
position as the only source for a scalable supply of cGMP-grade
HMW-KLH for the vaccine business. We have put Stellar's aquaculture
KLH supply front and center in combination with what we believe is
the most important manufacturer and marketer of cGMP biologics in
the world, Sigma-Aldrich's SAFC business unit. This exciting
development will allow us to move aggressively forward on our
diagnostic programs, knowing that the state-of-the-art quality
assurance and production capabilities of SAFC will be providing the
backbone for companies seeking the highest quality HMW-KLH
available for vaccine developers anywhere in the world. We look
forward to continuing growth in this relationship and will begin
manufacture of SAFC's initial order as soon as possible."
About High Molecular Weight KLH: HMW KLH
is an ideal carrier molecule for vaccine antigens (substances that
promote the generation of antibody and cell-mediated immune
responses) against cancers and infectious agents. The combination
of an antigen against specific tumor cell-types, conjugated to the
highly immunogenic HMW KLH molecule, is the basis for a proven
strategy for a new class of drugs known as therapeutic vaccines.
Potent yet safe in humans, KLH is highly prized as a critical
component of certain therapeutic vaccines including ones for
lymphoma, bladder, breast, colon and other cancers as well as other
indications including Alzheimer's, rheumatoid arthritis, lupus and
others.
About SAFC®: SAFC is the custom
manufacturing and services business unit of Sigma-Aldrich
Corporation (NASDAQ: SIAL). They are recognized as a top 10 global
fine chemical supplier and trusted manufacturer of specialty
chemicals and biologics for the life science and high technology
industries. Utilizing global "Centers of Excellence" and dedicated
manufacturing facilities, SAFC is often able to resolve development
and manufacturing challenges and accelerate the production of
custom materials. Their rich portfolio includes high-purity
inorganic materials for high technology applications, cell culture
products, services for biopharmaceutical manufacturing and
biochemical production, and complex, multi-step organic synthesis
of APIs and key intermediates. For more information about SAFC,
visit www.safcglobal.com.
About Sigma-Aldrich (NASDAQ: SIAL):
Sigma-Aldrich is a leading Life Science and High Technology
company. Its biochemical and organic chemical products and kits are
used in scientific and genomic research, biotechnology,
pharmaceutical development, the diagnosis of disease and as key
components in pharmaceutical and other high technology
manufacturing. The Company has customers in life science companies,
university and government institutions, hospitals, and in industry.
Over one million scientists and technologists use its products.
Sigma-Aldrich operates in 40 countries and has 8,300 employees
providing excellent service worldwide. Sigma-Aldrich is committed
to Accelerating Customer Success through Innovation and Leadership
in Life Science, High Technology and Service. For more information
about Sigma-Aldrich, please visit its award-winning Web site at
www.sigma-aldrich.com.
SAFC and Sigma-Aldrich are registered trademarks of
Sigma-Aldrich Co. LLC.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF)
(www.StellarBiotechnologies.com) is the world leader in sustainable
manufacturing of pharmaceutical grade KLH (Keyhole Limpet
Hemocyanin). This evolutionary protein has a highly complex
structure that makes it ideal for use in human and animal vaccines
and diagnostic products. With partners and customers, its flagship
Stellar KLH products are in the clinic, and on the way to being
established as the only sustainable, long-term pharmaceutical
source. Stellar Biotechnologies was founded to address the growing
demand for renewable, commercial-scale supplies of high-quality,
GMP-grade KLH. Stellar has developed leading practices, facilities
and proprietary capabilities to address this need.
There can be no assurance that forward-looking statements will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Readers should not place undue reliance on such statements. Except
in accordance with applicable securities laws, the Company
expressly disclaims any obligation to update any forward-looking
statements or forward-looking statements that are incorporated by
reference herein. This news release does not constitute an offer to
sell, or a solicitation of an offer to buy any of the Company's
securities set out herein in the United States, or to, or for the
benefit or account of, a U.S. Person or person in the United
States. Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
these releases.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Michael McClurg VP, Business Development &
Marketing 322 Scott Street Port Hueneme, CA 93041 (805) 488-2147
cell - 858 735 6117 mmcclurg@StellarBiotech.com
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From May 2024 to Jun 2024
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From Jun 2023 to Jun 2024